Osteoporosis: Which current treatments reduce fracture risk?

Cleveland Clinic Journal of Medicine

Volumn 67, Issue 10, 2000, Pages 701-703

  Baran, Daniel T ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CONJUGATED ESTROGEN; ESTROGEN DERIVATIVE; ETIDRONIC ACID; MEDROXYPROGESTERONE ACETATE; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; VITAMIN D;

ARTICLE; BONE DENSITY; BONE TURNOVER; DRUG CHOICE; DRUG EFFICACY; FRACTURE; HUMAN; OSTEOPOROSIS; RISK MANAGEMENT;

EID: 0033779169     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.67.10.701     Document Type: Article

References (13)

1. Kanis JA, McCloskey EV. Risk factors in osteoporosis. Maturitas 1998; 30:229-233.
2. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282:637-645.
3. Dawson-Hughes B, Harris SS, Krall EA, Dallai GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337:670-676.
4. LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 1999; 281:1505-1511.
5. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995; 122:9-16.
6. Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowitz M. Hip fracture and the use of estrogens in postmenopausal women: the Framingham study. N Engl J Med 1987; 317:1169-1174.
7. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117:1-9.
8. Silverman SL, Chesnut C, Andriano K et al for the PROOF Study group. Salmon calcitonin nasal spray (NS-CT) reduces risk of vertebral fracture(s) in established ostecporosis and has continuous efficacy with prolonged treatment: Accrued 5 year worldwide data of the PROOF study [abstract]. Bone 1998; 23(Suppl):S174.
9. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348:1535-1541.
10. Cummings S, Black D, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998; 280:2077-2082.
11. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999; 282:1344-1352.
12. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronete on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporosis International 2000; 11:83-91.
13. Miller P, Roux C, McClung M, et al. Risedionate reduces hip fractures in patients with low femoral neck bone mineral density [abstract]. Arth Rheum 1999; 42(Suppl):S287.